AddedRisk Factors
The Consolidated Appropriations Act of 2026 reauthorized the FDA’s authority to award priority review vouchers to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029. Under current law, after September 30, 2029, the FDA may not award any rare pediatric disease priority review vouchers, although the FDA’s authority to do so could be extended by Congress in the future.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedRisk Factors
In September 2025, the FDA announced increased scrutiny of advertising and promotional practices, with a particular focus on direct-to-consumer (“DTC”) advertising and reportedly sent thousands of letters to pharmaceutical companies to remove misleading ads, including a large number of untitled and warning letters citing allegedly misleading claims. For example, we received one of these untitled letters citing a DTC broadcast advertisement for Attruby. This heightened enforcement environment increases the risk that our promotional materials, even if we believe them to be compliant, could be challenged by the FDA or by consumers or plaintiffs’ counsel, which could lead us to modify or withdraw certain promotional materials. If we cannot successfully manage the promotion of our products or product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedRisk Factors
The drug product for Attruby and Beyonttra is currently supplied by one primary supplier. Although we have entered into a master agreement with an alternative supplier of drug product for this commercial product and expect the initial commercial batch of this material to be released to us later this year from this secondary supplier, we may encounter unexpected delays in the manufacture and supply of commercial drug product.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedRisk Factors
With the change in the U.S. Presidential Administration in 2025, there continues to be substantial uncertainty as to whether and how the current administration will seek to modify or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over our product candidates and any products for which we obtain approval. This uncertainty could present new challenges as we navigate development and approval of our product candidates. Some of these efforts have manifested to date in the form of personnel cuts and measures that could impact the FDA’s ability to hire and retain key personnel, which could result in delays or limitations on our ability to obtain guidance from the FDA on our product candidates in development and obtain the requisite regulatory approvals in the future. There remains general uncertainty regarding future activities. The current administration could issue or promulgate executive orders, regulations, policies or guidance that adversely affect us or create a more challenging or costly environment to pursue the development of new therapeutic products. Alternatively, state governments may attempt to address or react to changes at the federal level with changes to their own regulatory frameworks in a manner that is adverse to our operations. If we become negatively impacted by future governmental orders, regulations, policies or guidance as a result of the current Administration, there could be a material adverse effect on us and our business.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RemovedRisk Factors
recruitment for clinical trials. See the section titled, “Business - Government Regulation - Other Regulatory Matters.”
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
commercialize Attruby and Beyonttra and our other product candidates, if approved. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
•the demand for Attruby and Beyonttra and our other product candidates, if approved;
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
The FDA’s rare pediatric disease priority voucher program began to sunset on December 20, 2024, on failure to pass a continuing resolution package that included its reauthorization. Under the amended statutory sunset provisions, after December 20, 2024, the FDA may award a PRV for an approved rare pediatric disease product application only if the sponsor has rare pediatric disease designation for the drug and if that designation was granted by December 20, 2024. After September 30, 2026, the FDA may not award any rare pediatric disease PRVs. Congress may vote to reauthorize this program, but its future remains unknown at this time. Absent such legislative reauthorization of the program, if an NDA for BBP-812 is not approved prior to September 30, 2026 for any reason, regardless of whether it meets the criteria for a rare pediatric disease PRV, it will not be eligible for a PRV.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
We may seek designation for our platform technology as a designated platform technology. A sponsor may request the FDA to designate a platform technology as a designated platform technology concurrently with, or at any time after, submission of an IND application for a drug that incorporates or utilizes the platform technology that is the subject of the request. If so designated, the FDA may expedite the development and review of any subsequent original NDA or BLA for a drug that uses or incorporates the platform technology. Even if we believe our platform technology meets the criteria for such designation, the FDA may disagree and instead determine not to grant such designation. In addition, the receipt of such designation for a platform technology does not ensure that a drug will be developed more quickly or receive a faster FDA review process or ultimate FDA approval. Moreover, the FDA may revoke a designation if the FDA determines that a designated platform technology no longer meets the criteria for such designation. See the section titled, “Business — Government Regulation — Expedited Development and Review Programs.”
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
Manufacturers and manufacturers’ facilities are required to comply with extensive requirements imposed by the FDA and comparable foreign regulatory authorities, including ensuring that quality control and manufacturing
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
If we or one of our licensing partners initiated legal proceedings against a third party to enforce a patent covering one or more of our product candidates, the defendant could counterclaim that the patent covering the relevant product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest rates below current market interest rates. Although the U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by certain of such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediate liquidity may exceed the capacity of such program. Additionally, there is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
commercialize product candidates if approved, and compete effectively will depend, in part, on our ability to effectively manage any future growth.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
Although the EU GDPR and the UK GDPR currently impose substantially similar obligations, it is possible that over time the UK GDPR could become less aligned with the EU GDPR, particularly with the introduction of the
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
We have incurred indebtedness under our convertible senior notes and are party to a financing agreement that contains operating and financial covenants that may restrict our business and financing activities.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RewordedRisk Factors
Inadequate funding for Disruptions to the operations of the FDA, the SEC and other government agencies, including from government shut downs, or other disruptions comparable regulatory authorities caused by funding shortages or global health concerns, in addition to substantial uncertainty regarding the current Administration’s initiatives and staffing cuts and how these agencies’ operations, might impact the FDA, its implementation of laws, regulations, policies and guidance, and its personnel, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, including timely reviews, which could negatively impact our business.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
If one or more holders elect to convert their Notes, unless we elect to may satisfy our conversion obligation by delivering solely obligation, at our election, in cash, shares of our common stock, or a combination of cash and shares of our common stock (other than paying cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation through the payment of cash, which could adversely affect our liquidity. share).
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
We do not currently have any other suppliers for the drug substance or drug product of for these product candidates and, although we believe that there are alternate sources of supply that could satisfy our clinical requirements and commercial requirements, are in the process of establishing agreements with alternate suppliers, we cannot assure you that we will be successful in identifying alternate sources and establishing relationships with such sources would not result in sources, or that we will be able to avoid significant delay delays or disruptions in the development of our product candidates. candidates due to our current reliance on single-source suppliers.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
We may also fail to obtain or maintain the necessary regulatory approvals, distribution licenses or other registrations that are required to ship an approved product to a customer or commercial partner. partner, or our contract manufacturers may fail to supply us or our commercial partners with our required or forecasted amounts of finished product, active pharmaceutical ingredients or raw materials to meet commercial demand on a timely basis, or at all.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our vendors may also in turn incorporate generative artificial intelligence AI tools into their offerings without disclosing this use to us, offerings, and the providers of these generative artificial intelligence AI tools may not meet existing or rapidly evolving regulatory or industry standards standards, including with respect to privacy and data protection and may inhibit our or our vendors’ ability to maintain an adequate level of service and experience. security.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
If a prolonged government shutdown occurs, or disruption to the operations of if geopolitical or global health concerns prevent the FDA or other regulatory authorities occurs, from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or such other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. business, including INDs placed on clinical holds or delayed new drug approvals.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
If the Seller Parties we are unable to comply with applicable obligations, the Purchasers purchasers under the Royalty Purchase Agreement or the Funding Agreement, as applicable, may be entitled to take exercise remedies against their respective collateral securing our obligations, including taking possession of such assets, assets under the Funding Agreement, which could have a material adverse effect on our business, financial condition and results of operations.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
We could also encounter delays if an ongoing or planned clinical trial is suspended or terminated by us, by the data safety monitoring board (“DSMB”) including for our ongoing Phase 3 clinical trial of low-dose infigratinib, our ongoing Phase 2 and planned Phase 3 clinical trials of BBP-418, and our ongoing Phase 3 clinical trial of encaleret, (“DSMB”), or by the FDA or other regulatory authority, or if the IRBs of the institutions in which such trials are being conducted suspend or terminate the participation of their clinical investigators and sites subject to their review.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our We have recorded significant restructuring charges from our corporate restructuring initiatives, including any associated workforce reductions or reorganizations, and may do so again in the future, which could have a material negative impact on our results of operations, may not result in the full anticipated savings savings, and may disrupt operations.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Under For example, under the Funding Agreement, the Seller Parties we are required to comply with various covenants, including using use commercially reasonable efforts to obtain regulatory approval for and commercialize Attruby, providing provide the Funding Agreement Purchasers with certain clinical, commercial, regulatory and intellectual property updates and certain financial statements, and providing provide notices upon the occurrence of certain events, each as agreed under the Funding Agreement. events.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our business is substantially dependent on our ability to successfully commercialize AttrubyTM and BeyonttraTM, and the The continued commercial success of Attruby and Beyonttra or any other this product, along with our product candidates, if approved, will depend upon the degree of market acceptance by physicians, patients, healthcare payors, and others in the medical community.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past past, such as in the case of the closure and subsequent placement into receivership with the Federal Deposit Insurance Corporation (“FDIC”) of Silicon Valley Bank in March 2023, and may in the future lead to market-wide liquidity problems.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Many Some of our product candidates are in early-stage research or translational phases of development, and the risk of failure for these programs is high.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
While new AAV vectors have been developed to reduce some of these side effects, gene therapy is still a relatively new approach to disease treatment and additional adverse side effects could develop.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
BridgeBio Pharma, Inc. (“BridgeBio,” the “Company,” or “we”), is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases. We seek to translate advances in genetic science into therapies for patient populations with significant unmet medical needs.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
On June 27, 2025 (the “Closing Date”), we and our subsidiary, Eidos Therapeutics, Inc. (“Eidos”), entered into a Royalty Interest Purchase and Sale Agreement (the “Royalty Purchase Agreement”) with Acoramidis Royalty SPV, LP (“ARS”), an affiliate of HealthCare Royalty Management, LLC (“HCRx”), as a purchaser and the purchaser representative (in such capacity, the “Purchaser Representative”), and LSI Financing Fund, LP, an affiliate of Blue Owl Capital Corporation, as a purchaser (together with ARS as a purchaser and any future permitted assignees of a purchaser, the “Royalty Agreement Purchasers”). Subsequent to the Closing Date, on July 30, 2025, KKR & Co. Inc., a beneficial holder of our common equity and a related party, acquired a majority ownership interest in HCRx. Accordingly, HCRx became our related party following KKR & Co. Inc.’s acquisition of HCRx.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Pursuant to the Royalty Purchase Agreement, Eidos sold to the Royalty Agreement Purchasers certain of Eidos’ right to receive certain royalty payments (“Purchased Royalty Payment”) on net sales of certain products containing acoramidis (the “Licensed Products”) made in the European Union (“EU”) and all member and extension states of the European Patent Organization (the “Licensed Territory”) under (i) an exclusive license agreement, dated as of March 1, 2024, by and among Bayer Consumer Care AG (“Bayer”), Eidos and our other subsidiaries party thereto, as amended from time to time (the “Bayer License Agreement”) and (ii) an amended and restated license agreement, effective as of June 30, 2023, by and between Eidos and our other subsidiary, BridgeBio International GmbH. As consideration for the sale of the Purchased Royalty Payment, the Royalty Agreement Purchasers agreed to pay Eidos $300.0 million in cash (the “Purchase Price”), which was funded in full on the Closing Date. The Royalty Agreement Purchasers’ rights to the Purchased Royalty Payment are subject to (a) an annual cap equal to 60% of all royalty payments paid by Bayer to Eidos and its affiliates under the Bayer License Agreement on the first $500.0 million of annual net sales of Licensed Products in the Licensed Territory under the Bayer License Agreement and (b) an initial hard cap equal to 145% of the Purchase Price. Refer to Liquidity and Capital Resources section for additional details regarding this agreement.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
On January 17, 2024, we and our subsidiaries, Eidos, BridgeBio Europe B.V. and BridgeBio International GmbH (collectively, the “Seller Parties”), entered into a Funding Agreement (the “Funding Agreement”) with LSI Financing 1 Designated Activity Company and CPPIB Credit Europe S.à r.l. (together and with any future permitted assignees of a seller party, the “Funding Agreement Purchasers”), and Alter Domus (US) LLC, as the collateral agent. In connection with the Royalty Purchase Agreement described above, the Funding Agreement was amended on June 27, 2025. All terms and conditions of the Funding Agreement remain substantially unchanged. Refer to Liquidity and Capital Resources section for additional details regarding this agreement.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
(1)Including a related party amount of $(10,944) for the year ended December 31, 2025 (as described in Note 10 to our consolidated financial statements).
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Total revenues, net increased by $280.2 million for the year ended December 31, 2025, compared to 2024, which consisted of an increase of $359.5 million in net product revenue, a decrease of $90.5 million in license and services revenue, and an increase of $11.2 million in royalty revenue.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Net product revenue for the year ended December 31, 2025 was $362.4 million. This revenue was generated from the commercial sale of Attruby in the U.S. following FDA approval in November 2024.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Royalty revenue for the year ended December 31, 2025 was $11.4 million. This revenue primarily relates to royalties earned from net product sales of Beyonttra in the EU, following EC approval in February 2025, and in Japan, following pricing approval in May 2025.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Total cost of revenues increased by $17.1 million for the year ended December 31, 2025, compared to 2024, primarily due to an increase of $14.3 million in cost of goods sold and an increase of $2.8 million in cost of license, services, and royalty revenue.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Cost of goods sold for the years ended December 31, 2025 and 2024 consists of manufacturing costs, transportation and freight-in, and indirect overhead costs (including salary and benefits related and stock-based compensation expenses) associated with the commercial manufacturing and distribution of Attruby, and third-party royalties associated with our net product revenue. We began incurring cost of goods sold following FDA approval and commercial launch of Attruby in November 2024.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Cost of license, services, and royalty revenue for the years ended December 31, 2025 and 2024, consists mainly of third-party royalties associated with commercial sales of Beyonttra, manufacturing costs relating to product supply of Beyonttra to our collaboration partners, and amortization of intangible assets for milestones achieved upon FDA approval from our license and collaboration agreements. We began incurring royalties and manufacturing costs associated with commercial sales of Beyonttra upon its approval in the EU, Japan, and the UK in 2025.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Research and development expenses decreased by $54.5 million for the year ended December 31, 2025, compared to 2024. The decrease consisted of a $32.4 million decrease in external costs, a $9.4 million decrease in personnel-related expenses, and a $0.6 million decrease in stock-based compensation expenses, which are collectively primarily driven by decreased R&D activities related to the Attruby and Beyonttra program following regulatory approval and the reprioritization of our R&D programs. In addition, there was a $12.1 million decrease in license fees due to timing of milestones achieved.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RemovedMD&A
BridgeBio Pharma, Inc. (“we” or the “Company”) is a new type of biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
GondolaBio was formed on June 5, 2024 and we were the sole member. On August 16, 2024, based on the recommendation of a special committee of independent and disinterested directors of BridgeBio, we entered into a
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
transaction agreement (the “Transaction Agreement”) providing for the formation and funding by certain third party investors of GondolaBio, LLC, a Delaware limited liability company (“GondolaBio”), a legal joint venture entity for the purpose of researching, developing, manufacturing and commercializing pharmaceutical products, including certain assets contributed to GondolaBio by BridgeBio. The investors providing financing to GondolaBio consist of an investor syndicate, including Viking Global Investors LP, Patient Square Capital, Sequoia Capital, Frazier Life Sciences, Cormorant Asset Management, Aisling Capital and an entity owned by Neil Kumar, the Company’s Chief Executive Officer. The investors have committed $300.0 million of tranched financing to GondolaBio, of which $60.0 million had been contributed during the period August 16, 2024 through December 31, 2024. We contributed certain assets and our equity in Portal Therapeutics, Inc. and Sub21, Inc. to GondolaBio. Upon completion of the initial contributions, the Company’s equity ownership in GondolaBio was 45.5%, which had a fair value of $50.0 million, and will be subject to reduction as additional tranches of capital contributions are funded. On August 16, 2024, in conjunction with the Transaction Agreement, GondolaBio’s limited liability company agreement was amended and restated to reflect a change in its governance structure and composition of the board of managers, which was determined to be a VIE reconsideration event. Based on the VIE reconsideration assessment, GondolaBio was deemed a VIE. As a result of the change in governance structure and composition of the board of managers, we are no longer the primary beneficiary, as we no longer have the power over key decisions that significantly impact GondolaBio’s economic performance. Accordingly, we deconsolidated GondolaBio, inclusive of Portal Therapeutics, Inc. and Sub21, Inc., on August 16, 2024. On August 16, 2024, we recognized an approximate $52.0 million net gain from deconsolidation of subsidiaries which is presented on the consolidated statements of operations for the year ended December 31, 2024. Upon the deconsolidation of GondolaBio on August 16, 2024, we accounted for our investment in GondolaBio, for which we had significant influence through our ownership interest, using the equity method of accounting. GondolaBio was also deemed a related party. For the period August 16, 2024 through December 31, 2024, we recognized a net loss from equity method investment of $8.5 million. As of December 31, 2024, the aggregate carrying amount of our equity method investment in GondolaBio is $41.5 million and is presented as part of “Investment in nonconsolidated entities” on our consolidated balance sheets.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
On April 30, 2024, TheRas, Inc., doing business as BridgeBio Oncology Therapeutics (BBOT), a majority-owned subsidiary of the Company, completed a $200.0 million private equity financing with external investors to accelerate the development of its oncology portfolio. As part of the private equity financing transaction, BBOT’s Certificate of Incorporation and Investors’ Rights Agreement were amended and restated to reflect a change in BBOT’s governance structure and composition of the board of directors, which was determined to be a VIE reconsideration event. Based on the VIE reconsideration assessment, BBOT was deemed a VIE. As a result of the change in the governance structure and composition of the board of directors, we are no longer the primary beneficiary of BBOT, as we no longer have the power over key decisions that significantly impact BBOT’s economic performance. Accordingly, we deconsolidated BBOT on April 30, 2024. On April 30, 2024, we recognized a $126.3 million gain from deconsolidation of subsidiaries which is presented on the consolidated statements of operations for the year ended December 31, 2024. Upon the deconsolidation of BBOT, BridgeBio accounted for its retained investments in BBOT, for which it has significant influence through its ownership interest, using the equity method of accounting. BBOT was also deemed a related party. For the period from May 1, 2024 through December 31, 2024, we recognized a net loss from equity method investment of $22.7 million. As of December 31, 2024, the aggregate carrying amount of our equity method investment in BBOT is $102.2 million and is presented as part of “Investment in nonconsolidated entities” on our consolidated balance sheets.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
Supply Agreement with an initial 30-month term ending in December 2026, for which BridgeBio B.V. will manufacture and supply to Bayer the commercial product ordered by Bayer solely for the use in the commercialization in the Licensed Territory under the Bayer License Agreement. Under the Bayer Supply Agreement, Bayer shall pay to BridgeBio B.V. a commercial product per unit price equal to the applicable fully burdened manufacturing cost per unit of product, which shall include the cost of the API used to manufacture the product and the packaging price. As of December 31, 2024, there have been no commercial product supply sales to Bayer. The condition for the $75.0 million regulatory-based milestone payment was achieved upon the EC approval of Beyonttra on February 10, 2025. The Company anticipates receiving this milestone payment from Bayer in April 2025.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
Since our inception, we have created wholly-owned subsidiaries or made investments in certain controlled entities, including partially-owned subsidiaries for which we have majority voting interest under the VOE model or for which we are the primary beneficiary under the VIE model, which we refer to collectively as our consolidated entities. Ownership interests in consolidated entities that are held by entities other than us are reported as redeemable convertible noncontrolling interests and noncontrolling interests in our consolidated balance sheets. Losses attributed to redeemable convertible noncontrolling interests and noncontrolling interests are reported separately in our consolidated statements of operations.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
We have included our financial results for 2024 compared to 2023. Our financial results for 2023 compared to 2022 can be found in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (the “SEC”), on February 22, 2024 and is incorporated herein by reference.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
The results of operations for the years ended December 31, 2024 and 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2025 or for any other future annual or interim period.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
Under the terms of the Amended Financing Agreement, the Company is required to deposit 75% of proceeds, net of certain permitted costs, received from certain asset sale transactions into an escrow account to be controlled by the Administrative Agent. During the three months ended June 30, 2024, we received $235.0 million in aggregate from Bayer and Kyowa Kirin, and deposited net proceeds of $159.3 million into the escrow accounts, which was classified as “Restricted cash” on the consolidated balance sheet. Furthermore, under the terms of Amended Financing Agreement, between June 20, 2024 and through the earlier of the FDA approval date or November 30, 2024, the Company was able to request a release of funds in an aggregate amount not to exceed 50% of the original net cash proceeds received from asset sale transactions. During the three months ended June 30, 2024, $20.0 million was released from the escrow accounts. Following the FDA approval of Attruby in November 2024 and receipt of consent from the lenders, the remaining $139.3 million was released from the escrow accounts and classified as cash on the consolidated balance sheet.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
Restricted cash as of December 31, 2023 primarily represents funds in a controlled account that was established in connection with the Loan and Security Agreement (“Amended Loan Agreement”) that is described in Note 9. The use of such non-interest-bearing cash was restricted per the terms of the underlying amended loan agreement and was to be used solely for certain research and development expenses directly attributable to the performance of obligations associated with the Navire-BMS License Agreement, which is further described in Note 11. Upon the termination of the Amended Loan Agreement and full repayment of the term loan in January 2024 (refer to Note 9 for details), the non-interest-bearing cash was no longer restricted.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
On January 17, 2024, we paid our outstanding term loan principal balance under our Amended Loan Agreement with the proceeds from the Amended Financing Agreement plus additional cash from our operations. Under the Amended Financing Agreement, we were extended a senior secured credit facility of $450.0 million in an aggregate principal amount for the Initial Term Loan, which is subject to variable interest rates. As a result of the variable interest rates under our Amended Financing Agreement and Funding Agreement we expect our interest expense will continue to fluctuate in the future. Refer to the Liquidity and Capital Resources section below and Note 9 for details regarding the Term Loan and the Amended Financing Agreement.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
On January 17, 2024, we entered into the Financing Agreement with certain of our subsidiaries party thereto as guarantors, the Lenders and the Administrative Agent, which was amended on February 12, 2024.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RewordedMD&A
Year Years Ended December 31, 2025 2024 2023 (in thousands) Revenue Total revenues, net $ 502,076 $221,902 $9,303 Cost Total cost of revenue 3,878 2,446 revenues $ 20,962 $3,878 Research and development 506,461 455,711 $ 451,953 $506,461 Selling, general and administrative 288,931 150,590 $ 531,225 $288,931 Restructuring, impairment impairment, and related charges 15,605 7,926 $ 21,347 $15,605 Loss from operations (592,973) (607,370) $ (523,411) $(592,973) Interest income 17,249 18,038 $ 19,854 $17,249 Interest expense (99,290) (81,289) $ (53,103) $(90,991) Noncash interest expense on deferred royalty obligations (1) $ (125,138) $(8,299) Gain on deconsolidation of subsidiaries 178,321 $ — $178,321 Loss on extinguishment extinguishments of debt (26,590) — $ (21,155) $(26,590) Net loss from equity method investments (31,183) — $ (72,608) $(31,183) Other income, net $ 43,058 $12,272 Provision for income (expense), net 12,272 17,370 Income tax expense 1,153 — taxes $ 435 $1,153 Net loss (543,347) (653,251) $ (732,938) $(543,347) Net loss attributable to redeemable convertible noncontrolling 7,585 10,049 interests and $ 8,007 $7,585 noncontrolling interests Net loss attributable to common stockholders of BridgeBio (535,762) (643,202) $ (724,931) $(535,762)
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash used in operating activities was $520.7 million in 2024, consisting primarily of our net loss of $543.3 million; adjusted The adjustments for non-cash noncash items totaling $9.4 million, which million primarily includes included a gain of $178.3 million from the deconsolidation of subsidiaries, and a net gain of $8.1 million from investment in equity securities, and securities; partially offset by $95.8 million in stock-based compensation expense, $31.2 million net loss from equity method investments, $26.6 million in loss on extinguishment of debt from the repayment of the term loan under the Amended Loan Agreement, $15.8 $8.3 million in noncash interest expense on deferred royalty obligations, $7.5 million in accretion of debt, and $6.1 million in depreciation and amortization; and a $32.0 million net cash inflow related to changes in operating assets and liabilities. amortization.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
On January 17, 2024, we entered into a Financing Agreement with each of the guarantors, which was amended on February 12, 2024 (the “Financing Agreement”) and June 20, 2024 (the Financing Agreement, as amended by the Second Amendment, the “Amended Financing Agreement”), with certain of our subsidiaries party thereto as guarantors, the lenders party thereto (the “Lenders”) and Blue Owl Capital Corporation, as administrative agent for the Lenders (the “Administrative Agent”), which was amended on February 12, 2024 and June 20, 2024 (the Financing Agreement, as amended by the second amendment, the “Amended Financing Agreement”). Agent”).
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
In the event that a change in of control (as customarily defined in the Funding Agreement) occurs on or after the effective date of the Funding Agreement Agreement, the Purchasers may elect to require the Seller Parties to make the Buy-Out Payment and prior to FDA approval of acoramidis, either party may terminate the Funding Agreement and will be terminated upon payment in-full of the Seller Parties shall make a one-time payment of $25.0 million (in Parties’ obligations under the aggregate) to Funding Agreement (including the Purchasers. Buy-Out Payment and all reimbursable expenses).
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Our short-term and long-term liquidity requirements include contractual payments related to our 2033 Notes (refer to Note 19 to our consolidated financial statements), 2031 Notes, 2029 Notes, and 2027 Notes and term loan (refer to Note 9 to our consolidated financial statements, accounts payable, accrued liabilities), statements), our deferred royalty obligation obligations, net under the Funding Agreement and Royalty Purchase Agreement (refer to Note 10 to our consolidated financial statements), as well as obligations under our real estate leases (refer to Note 14 13 to our consolidated financial statements) statements), accounts payable, accrued liabilities and the remaining liabilities under our restructuring initiative (refer to Note 17 16 to our consolidated financial statements).
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
In consideration for the license grant, the Seller Parties received are entitled to receive an upfront payment of $135.0 million million, which was received in full in May 2024, and will be eligible to receive up to $150.0 million in regulatory and sales milestone payments through 2026 (of which $75.0 million is for a regulatory milestone dependent of $75.0 million was achieved in February 2025 upon EC approval of acoramidis on or before December 31, under the brand name Beyonttra and received in April 2025), and additional payments up to $450.0 million subject to the achievement of certain sales milestones.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Year Years Ended December 31, 2025 2024 2023 (in thousands) Acoramidis for the treatment of ATTR-CM and primary prevention in $ 116,844 $ 164,782 $ 101,041 asymptomatic carriers of a pathogenic TTR variant Infigratinib for achondroplasia and hypochondroplasia 122,685 91,869 63,239 BBP-418 (ribitol) for LGMD2I/R9 56,008 40,220 33,903 Encaleret for ADH1 59,955 49,091 44,773 Other development programs 22,703 71,732 82,165 Other research programs 73,758 88,767 130,590 Total $ 451,953 $ 506,461 $ 455,711
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
In consideration for the license grant, the Seller Parties received an upfront payment of $135.0 million in May 2024 and will be eligible to receive up to $150.0 million in regulatory and sales milestone payments through 2026 (of which $75.0 million is for a regulatory milestone dependent of $75.0 million was achieved and recognized as license and services revenue in February 2025 upon EC approval of acoramidis on or before December 31, under the brand name Beyonttra and received in April 2025), and additional payments up to $450.0 million subject to the achievement of certain sales milestones.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Under the Eidos-Alexion License Agreement, Eidos received an upfront nonrefundable payment of $25.0 million million, and is eligible to receive in June 2025, Eidos received a regulatory milestone payment of $30.0 million in regulatory milestone payments and royalties in following pricing approval from the low-teens based on net sales of acoramidis National Health Insurance in Japan.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Interest expense consists primarily of interest expense incurred under our 2031 Notes issued in February 2025, our 2029 Notes issued in January 2021, and our 2027 Notes issued in March 2020, our term loan under the Amended Financing Agreement, our term loan under the Amended Loan Agreement, and our deferred royalty obligation under the Funding Agreement. 2020.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
On January 17, 2024, the Company we and its subsidiaries Eidos Therapeutics, Inc., Eidos, BridgeBio Europe B.V. and BridgeBio International GmbH (collectively, the “Seller Parties”) entered into the a Funding Agreement (the “Funding Agreement”) with the Purchasers, LSI Financing 1 Designated Activity Company and Alter Domus (US) LLC, as the collateral agent. CPPIB Credit Europe S.à r.l.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
As of December 31, 2024, 2025, we had cash and cash, cash equivalents and marketable securities of $681.1 million and restricted cash of $0.1 $587.5 million, compared to cash and cash equivalents of $375.9 million, restricted cash of $16.7 million and investment in equity securities of $58.9 $681.1 million as of December 31, 2023. 2024.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new